Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

NCT01805557 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
108
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fondazione Italiana Linfomi - ETS

Collaborators